Case Reports

Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel


 

Drug-induced immune hemolytic anemia is rare, with only 1 patient in 1 million affected by the condition. Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included. In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

ASCO 2015: from data and learning, to daily practice
MDedge Hematology and Oncology
Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Inflammatory metastatic breast cancer with gallbladder metastasis: an incidental finding
MDedge Hematology and Oncology
Nodal irradiation improved breast cancer disease-free but not overall survival
MDedge Hematology and Oncology
Aromatase inhibitors, bisphosphonates cut postmenopausal breast cancer recurrence
MDedge Hematology and Oncology
ASCO guidelines define use of biomarkers for advanced breast cancer treatment
MDedge Hematology and Oncology
Younger breast cancer patients want tailored decision aids
MDedge Hematology and Oncology
Weight program effective for breast cancer survivors
MDedge Hematology and Oncology
Reduced invasive recurrence after DCIS does not reduce mortality
MDedge Hematology and Oncology
Evidence-based practices can cut breast cancer costs
MDedge Hematology and Oncology